125
Participants
Start Date
March 14, 2022
Primary Completion Date
May 28, 2024
Study Completion Date
May 28, 2024
Semaglutide
Patients will be treated for 24 weeks with semaglutide 3.0 mlg/ml s.c. once weekly. The starting dose of semaglutide will be 0.24 mg per week subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg.
Placebo
Patients will receive a matching placebo sc. once weekly during the treatment period of 24 weeks.
University of Calgary, Calgary
Hospital Da Costa Burela, Lugo
Hospital Clínico Universitario, Valencia
University Hospital Erlangen, Erlangen
University Hospital Wuerzburg, Würzburg
Division of Nephrology University Health Network, University of Toronto, Toronto
Rijnstate, Arnhem
Isala, Zwolle
University Medical Center Groningen, Groningen
Martini Ziekenhuis, Groningen
Dept Internal Medicine, division of Nephrology Hospital Group Twente, Almelo
Vall d'Hebron University Hospital, Barcelona
Hospital Universitari de Bellvitge, Barcelona
Collaborators (1)
Novo Nordisk A/S
INDUSTRY
University Medical Center Groningen
OTHER